VCP and acute myeloid leukemia: The newer analogue CB-5339, without the off-target effect has completed a phase one clinical trial for acute myeloid leukemia (AML) (NCT04402541) based on the genetic evidence of AML dependence on p97/VCP(Roux, 2021).